Ascendis Pharma is experiencing a dramatic commercial inflection, with Q2 2026 revenue growth accelerating to 118.2% year-over-year and operating income turning positive at $63.4M, driven by the ramp of SKYTROFA and initial YORVIPATH contributions. This revenu...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 118.2% year-over-year in Q2 2026, driving gross margins to a structurally high 90.6% and enabling operating income to expand to $63.4M, demonstrating clear operating leverage.
Ascendis Pharma's Transcon platform is highlighted as a key driver, offering innovative solutions in drug delivery and development.
The company's focus on rare diseases presents significant growth opportunities due to high unmet medical needs and favorable pricing.
Positive results from recent clinical trials bolster confidence in the company's ability to bring new therapies to market.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $3.29+92.4% vs $1.71 | $387M+2.8% vs $377M |
Q2 2026 May 7, 2026 | $0.32+70.6% vs $0.19 | $285M-7.8% vs $309M |
Q1 2026 Feb 11, 2026 | -$0.64-966.7% vs -$0.06 | $345M+18.0% vs $292M |
Q4 2025 Nov 12, 2025 | -$1.17-185.4% vs -$0.41 | $250M-17.3% vs $303M |
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They presently have a $300.00 price target on the biotechnology company's stock. Cantor Fitzgerald's price objective points to a potential upside of 32.98% from the company's
Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and Yuviwel—show robust growth, and Yorvipath net sales should exceed $1.1 billion this year. Yuviwel's strong U.S. launch and favorable BioMarin settlement provide freedom to operate.
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.
Benchmark ASND against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ascendis Pharma A/S (ASND)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $227.31 | $14.12B | -55.42 | 90.22% | -31.67% | — | — | |
| $44.00 | $7.31B | -18.49 | 33.87% | -64.64% | -110.84% | — | |
| $117.14 | $23.74B | 18.27 | 21.22% | 27.71% | 29.7% | — | |
| $40.54 | $6.8B | 28.35 | -5.25% | 3.96% | 3.72% | — | |
| $233.01 | $14.64B | -39.90 | 4.88% | 20.45% | 21.37% | — | |
| $19.89 | $3.41B | 8.69 | 11.87% | 33.42% | 32.39% | — |
Ascendis Pharma A/S (ASND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ASND posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ascendis Pharma A/S (ASND) stock FAQ — growth, dividends, profitability & financials explained
Ascendis Pharma A/S (ASND) reported $1.05B in revenue for fiscal year 2025. This represents a 6666% increase from $15.6M in 2012.
Ascendis Pharma A/S (ASND) grew revenue by 90.2% over the past year. This is strong growth.
Yes, Ascendis Pharma A/S (ASND) is profitable, generating $755.8M in net income for fiscal year 2025 (-31.7% net margin).
Ascendis Pharma A/S (ASND) generated $336.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
